461 related articles for article (PubMed ID: 22484817)
1. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
[TBL] [Abstract][Full Text] [Related]
2. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
Breevoort SR; Angdisen J; Schulman IG
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
[TBL] [Abstract][Full Text] [Related]
4. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
5. LXRalpha regulates human CETP expression in vitro and in transgenic mice.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Ubukata N; Terasaka N
Atherosclerosis; 2010 Sep; 212(1):139-45. PubMed ID: 20494359
[TBL] [Abstract][Full Text] [Related]
6. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptors as potential therapeutic targets in atherosclerosis.
Zhu Y; Li Y
Clin Invest Med; 2009 Oct; 32(5):E383-94. PubMed ID: 19796580
[TBL] [Abstract][Full Text] [Related]
9. Liver X receptor: a potential target in the treatment of atherosclerosis.
Savla SR; Prabhavalkar KS; Bhatt LK
Expert Opin Ther Targets; 2022 Jul; 26(7):645-658. PubMed ID: 36003057
[TBL] [Abstract][Full Text] [Related]
10. LXRα is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice.
Hong C; Bradley MN; Rong X; Wang X; Wagner A; Grijalva V; Castellani LW; Salazar J; Realegeno S; Boyadjian R; Fogelman AM; Van Lenten BJ; Reddy ST; Lusis AJ; Tangirala RK; Tontonoz P
J Lipid Res; 2012 Jun; 53(6):1126-33. PubMed ID: 22454476
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol efflux is LXRα isoform-dependent in human macrophages.
Ma AZ; Song ZY; Zhang Q
BMC Cardiovasc Disord; 2014 Jul; 14():80. PubMed ID: 24996838
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel partial agonist of liver X receptor α (LXRα) via screening.
Li N; Wang X; Zhang J; Liu C; Li Y; Feng T; Xu Y; Si S
Biochem Pharmacol; 2014 Dec; 92(3):438-47. PubMed ID: 25450668
[TBL] [Abstract][Full Text] [Related]
13. LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile.
Hu X; Steffensen KR; Jiang ZY; Parini P; Gustafsson JÅ; Gåfvels M; Eggertsen G
J Intern Med; 2012 Nov; 272(5):452-64. PubMed ID: 22329358
[TBL] [Abstract][Full Text] [Related]
14. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.
Bischoff ED; Daige CL; Petrowski M; Dedman H; Pattison J; Juliano J; Li AC; Schulman IG
J Lipid Res; 2010 May; 51(5):900-6. PubMed ID: 20388921
[TBL] [Abstract][Full Text] [Related]
15. Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism.
Zhang X; Liu J; Su W; Wu J; Wang C; Kong X; Gustafsson JÅ; Ding J; Ma X; Guan Y
J Diabetes; 2014 May; 6(3):212-20. PubMed ID: 23945440
[TBL] [Abstract][Full Text] [Related]
16. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha.
Lehrke M; Lebherz C; Millington SC; Guan HP; Millar J; Rader DJ; Wilson JM; Lazar MA
Cell Metab; 2005 May; 1(5):297-308. PubMed ID: 16054077
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis.
Millatt LJ; Bocher V; Fruchart JC; Staels B
Biochim Biophys Acta; 2003 Mar; 1631(2):107-18. PubMed ID: 12633677
[TBL] [Abstract][Full Text] [Related]
18. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
[TBL] [Abstract][Full Text] [Related]
19. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
[TBL] [Abstract][Full Text] [Related]
20. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
